Niemann-Pick C1-like 1 (NPC1L1) is a polytopic transmembrane protein that plays a critical role in cholesterol absorption. Ezetimibe, a hypocholesterolemic drug, has been reported to bind NPC1L1 and block cholesterol absorption. However, the molecular mechanism of NPC1L1-mediated cholesterol uptake and how ezetimibe inhibits this process are poorly defined. Here we find that cholesterol specifically promotes the internalization of NPC1L1 and that this process requires microfilaments and the clathrin/AP2 complex. Blocking NPC1L1 endocytosis dramatically decreases cholesterol internalization, indicating that NPC1L1 mediates cholesterol uptake via its vesicular endocytosis. Ezetimibe prevents NPC1L1 from incorporating into clathrin-coated vesicles and thus inhibits cholesterol uptake. Together, our data suggest a model wherein cholesterol is internalized into cells with NPC1L1 through clathrin/ AP2-mediated endocytosis and ezetimibe inhibits cholesterol absorption by blocking the internalization of NPC1L1.
INTRODUCTION
Cholesterol is an essential component of most biological membranes and is the precursor for synthesis of steroid hormones and bile acids. However, high levels of cholesterol cause severe problems including coronary heart disease (CHD). In developed societies, excessive dietary cholesterol uptake is a major risk factor for CHD. Mammals obtain cholesterol by de novo synthesis from acetyl-CoA and by absorption from diet and bile. Although much is known about the enzymology and regulatory pathways of cholesterol biosynthesis (Brown and Goldstein, 1986; Goldstein et al., 2006) , far less is understood about the molecular mechanisms by which cholesterol is absorbed.
Niemann-Pick C1-like 1 (NPC1L1) was recently identified as a critical player in the intestinal absorption of dietary cholesterol (Altmann et al., 2004) . It is highly expressed in small intestine and localized along the brush border in both human and mouse Altmann et al., 2004; Sane et al., 2006) . However, significant expression of NPC1L1 is also observed in human liver, but not in mouse liver (Davies et al., 2005; Altmann et al., 2004) . NPC1L1-deficient mice exhibit a drastic reduction of dietary cholesterol absorption (Davies et al., 2005; Davis et al., 2004; Altmann et al., 2004) . Besides mediating intestinal cholesterol uptake, overexpression of NPC1L1 in liver in a transgenic mouse model dramatically decreases biliary cholesterol concentration and increases plasma cholesterol level, indicating that liver NPC1L1 mediates biliary cholesterol reabsorption (Temel et al., 2007) . Taken together, these data indicate that NPC1L1 plays key roles in dietary and biliary cholesterol absorption in both intestine and liver.
The NPC1L1 protein contains about 1300 residues with 13 predicted transmembrane domains (Davies et al., 2000) . Interestingly, the third to seventh transmembrane helices constitute a sterol-sensing domain that is also present in other sterol-regulated proteins including NPC1, HMG-CoA reductase, and SCAP (Kuwabara and Labouesse, 2002) . NPC1L1 has been reported to localize on the plasma membrane (PM) (Altmann et al., 2004; Iyer et al., 2005) or in intracellular compartments (Davies et al., 2005; Sane et al., 2006) . More recently, Yu et al. found that NPC1L1 is transported from the endocytic recycling compartment (ERC) to the PM after cholesterol depletion and that only when localized on the PM can it promote cholesterol uptake (Brown et al., 2007; Yu et al., 2006) . Ezetimibe (trademark name Zetia) is a potent cholesterol absorption inhibitor that is being clinically used to treat hypercholesterolemia (Davis and Veltri, 2007) . NPC1L1 knockout mice show no response to ezetimibe (Altmann et al., 2004) , and the phenotypes of NPC1L1 transgenic mice can be normalized by ezetimibe (Temel et al., 2007) . These findings indicate that NPC1L1 and ezetimibe function in the same pathway. It has been further found that ezetimibe binds to brush-border membranes from wild-type animals but not those of NPC1L1 knockout mice, suggesting that ezetimibe interacts with NPC1L1 and presumably inactivates it (Davis and Veltri, 2007; Garcia-Calvo et al., 2005) . However, how ezetimibe inhibits NPC1L1-mediated cholesterol uptake is largely unknown.
In the present study, we find that NPC1L1 recycles between ERC and PM: depletion of cholesterol causes the transport of NPC1L1 from ERC to PM, whereas replenishment of cholesterol results in the transportation of NPC1L1 from PM to ERC. Meanwhile, cholesterol is internalized together with NPC1L1. Through disruption of microfilaments and knockdown of clathrin/AP2, we demonstrate that the endocytosis of NPC1L1 is dependent on microfilaments and the clathrin/AP2 complex. Blocking NPC1L1 endocytosis decreases cholesterol uptake, indicating that NPC1L1 mediates cholesterol uptake through vesicular endocytosis. We further find that ezetimibe blocks the internalization of NPC1L1, thereby inhibiting cholesterol uptake. In summary, our results reveal the mechanism of NPC1L1-mediated cholesterol uptake and how ezetimibe inhibits the process.
RESULTS
Cholesterol-Regulated Recycling of NPC1L1 between the Endocytic Recycling Compartment and Plasma Membrane To gain insights into the mechanism of NPC1L1-mediated cholesterol uptake, we established a cell line stably expressing NPC1L1-EGFP fusion protein from rat CRL-1601 hepatocytes and named it CRL-1601/NPC1L1-EGFP. Immunoblot analysis showed that similar levels of NPC1L1 protein are expressed in CRL-1601/NPC1L1-EGFP cells compared with human liver cell lines including HepG2, HuH7, and L02 (see Figure S1A available online). Therefore, this cell line was used as a model system to study the localization of NPC1L1. We first examined the localization of NPC1L1-EGFP at different time points after cellular cholesterol levels were altered. In normal cholesterolrich medium, NPC1L1-EGFP protein was mainly present in a perinuclear compartment ( Figure 1B , time point À60 min). Rab11a, an ERC marker (Ullrich et al., 1996) , showed a similar pattern and colocalized with NPC1L1-EGFP, indicating that NPC1L1 is in the ERC under this condition ( Figure S1B ). Consistent with the previous report of Yu et al. (2006) , after cells were refed with cholesterol-depleting medium, NPC1L1-EGFP gradually moved to the PM ( Figure 1B , time points À60 to 0 min). Also, $85% of the cells showed PM localization of NPC1L1-EGFP after depletion of cholesterol for 1 hr ( Figure 1C , time point 0 min). Interestingly, cholesterol replenishment induced the internalization of NPC1L1-EGFP, which became evident after only 30 min ( Figure 1B , time point 30 min). After 2 hr of cholesterol replenishment, NPC1L1-EGFP was transported back into the ERC and almost no cells showed surface localization ( Figure 1B , time points 30 to 120 min; Figure 1C , time point 120 min). This observation was confirmed using a cell surface biotinylation assay under the same treatment condition ( Figure 1D ). To further validate the localization of NPC1L1 and rule out the possible interference caused by this stable cell line, the subcellular localization of endogenous NPC1L1 protein was examined in L02 (a human liver cell line) cells, and the results consistently showed that endogenous NPC1L1 is similarly regulated by cholesterol ( Figure 1E ). These results demonstrate that the behavior of NPC1L1-EGFP can faithfully represent that of endogenous NPC1L1 protein.
Requirement of NPC1L1 for Free Cholesterol Uptake
In the process of low-density lipoprotein (LDL) cholesterol internalization, LDL binds to the extracellular domain of the LDL receptor (LDLR), which triggers clathrin-dependent vesicular endocytosis. These vesicles are transported away from the PM and fuse with the lysosome, where cholesterol esters are hydrolyzed and LDLR is resorted and moved back to the PM (Brown and Goldstein, 1986; Jeon and Blacklow, 2005) . Inspired by this mechanism, the observation of cholesterol-induced endocytosis of NPC1L1 led us to hypothesize that cholesterol is absorbed via the vesicular endocytosis of NPC1L1. To test this hypothesis, we stained cells with filipin, a sterol-binding fluorescent dye (Severs, 1997) , to indicate the amount and distribution of cellular cholesterol after various treatments. As shown in Figure 2A , cholesterol was barely observed in both CRL-1601 and CRL-1601/NPC1L1-EGFP cells after incubation in cholesterol-depleting medium for 60 min, while the majority of NPC1L1-EGFP was localized on the PM (Figure 2A , time point 0 min). When the cells were incubated in cholesterol-replenishing medium, the intracellular cholesterol gradually increased and the intensity of the filipin signal in CRL-1601/NPC1L1-EGFP cells was much stronger than that in control cells (Figure 2A , time points 30 to 120 min). Meanwhile, NPC1L1-EGFP was gradually transported into the cytoplasm and To exclude the variations of individual stable cell clones and test the cell type specificity, we also examined HEK293T cells transiently transfected with NPC1L1-EGFP. We found that the subcellular localization of NPC1L1-EGFP was regulated by cholesterol as well, and that cells overexpressing NPC1L1-EGFP took up more cholesterol than control cells ( Figure S2C ). Next, we utilized a retroviral vector-based RNA interference (RNAi) technique to reduce the expression of endogenous NPC1L1 in L02 cells (Figure 2C) . After knockdown of NPC1L1, the uptake of free cholesterol was decreased by $60% (Figures 2D and 2E ). Similar results were obtained when the endogenous NPC1L1 of HuH7 cells was knocked down by siRNA (data not shown). We also examined the efflux of cholesterol and found no dramatic difference between control and NPC1L1-overexpressing cells ( Figure S3 ), indicating that NPC1L1 is not required for cholesterol elimination and that the effect of NPC1L1 on cholesterol uptake in our system is a specific event. Together, these data demonstrate that NPC1L1 is necessary and sufficient for free cholesterol uptake in our system.
Specificity for NPC1L1-Mediated Internalization of Sterols
Mammals absorb about 50% of cholesterol from diet, compared to less than 5% of available plant sterols (Glover and Morton, 1958; Schoenheimer, 1931) . The structural differences between cholesterol and plant sterols are very small ( Figure 3A ). To explore whether NPC1L1 is involved in selective cholesterol absorption, we measured the sterol specificity of NPC1L1-mediated uptake by redelivering different sterols into cholesterol-depleted cells. As shown in Figure 3B , a massive amount of cholesterol was internalized into the cytoplasm together with NPC1L1. However, other sterols including ergosterol, b-sitosterol, campesterol, stigmasterol, and brassicasterol were poorly taken up. In parallel, the majority of NPC1L1 was still residing on the PM when cells were replenished with noncholesterol sterols ( Figure 3B , columns b-f). Fluorescence quantification revealed that $80% of cholesterol was localized in the cytoplasm, com- pared to 8%-13% of other sterols. For NPC1L1 subcellular distribution, a similar pattern was observed, with 85% intracellular localization after cholesterol replenishment and 12%-18% after other sterols were replenished ( Figure 3C ).
These data show that cholesterol is the most effective substrate of NPC1L1. Furthermore, the correlative localization of cholesterol and NPC1L1 suggests again that the internalization of cholesterol is cooperative with that of NPC1L1.
Disruption of Microfilaments Blocks NPC1L1 Endocytosis and Cholesterol Uptake
It is generally recognized that the cytoskeleton plays important roles in vesicular trafficking (Schafer, 2002; Apodaca, 2001) . The intracellular transport of NPC1L1 is likely reliant on the cytoskeleton network. To test this possibility and dissect the relationship between NPC1L1 endocytosis and cholesterol internalization, we utilized cytoskeleton-disturbing drugs to block the endocytosis of NPC1L1 and then measured cholesterol uptake. Cholesteroldepleted cells were treated with nocodazole (to depolymerize microtubules) (Lee et al., 1980) or cytochalasin D (to disrupt microfilaments) (Dubinsky et al., 1999) for 30 min. The cells were then replenished with cholesterol for various durations. In control and nocodazole-treated cells, NPC1L1 and cholesterol appeared in the vesicles beneath the PM after 30 min of cholesterol replenishment ( Figure 4B , time point 30 min). After an additional 60 min of treatment, NPC1L1 was completely endocytosed into intracellular vesicles, although nocodazole treatment disrupted the organization of the ERC (Vossenkamper et al., 2007; Yamashiro et al., 1984) and caused a diffused pattern of NPC1L1 and cholesterol in the cytoplasm ( Figure 4B ; Figure S4A ). Along with the endocytosis of NPC1L1, the cells took up a massive amount of cholesterol mostly colocalized with NPC1L1 in this process. However, in cytochalasin D-treated cells, the endocytosis of NPC1L1 was significantly blocked, and the uptake of cholesterol was also inhibited ( Figure 4B , bottom three rows). Fluorescence quantifications of the intracellular distribution of NPC1L1 and cholesterol are shown in Figure 4C . Using a cell surface biotinylation assay, we confirmed again that cytochalasin D, but not nocodazole, inhibited the endocytosis of NPC1L1 ( Figure 4D , compare lanes 5 to 7).
We also examined the exocytosis of NPC1L1 and cholesterol efflux after the cytoskeleton was disrupted. Similar to the endocytosis of NPC1L1, its exocytosis was not affected by nocodazole but was severely impaired by cytochalasin D, indicating that microfilaments are required for bidirectional transport of NPC1L1 ( Figure S4 ). However, the efflux of cholesterol was unaffected by either treatment ( Figure S4) . Thus, the endocytosis of NPC1L1 is required for cholesterol uptake, whereas the efflux of cholesterol is independent of the exocytosis of NPC1L1.
Loss of Clathrin/AP2 Attenuates NPC1L1 Endocytosis and Cholesterol Uptake To identify proteins involved in NPC1L1 endocytosis, we performed a large-scale immunoprecipitation with anti-EGFP agarose from detergent lysates of the membrane fraction of CRL-1601/NPC1L1-EGFP cells. Specific bands were identified by tandem mass spectrometry ( Figure S5 ), one of which was the m2 subunit of the AP2 complex. The AP2 adaptor complex, which consists of a, b2, m2, and s2 subunits, mainly functions to select cargo on the PM for inclusion into clathrin-coated vesicles in the endocytic pathway (Owen et al., 2004) . Coimmunoprecipitation experiments confirmed that NPC1L1-EGFP, m2, and clathrin heavy chain (CHC) are present in the same protein complex ( Figure S5C ). These data indicate that clathrin-mediated endocytosis is involved in the transport of NPC1L1 protein. This hypothesis was next addressed by diminishing CHC or m2 through RNAi.
CHC and m2 were substantially reduced by RNAi as revealed by western blot ( Figure 5A ). Knockdown of CHC or m2 dramatically inhibited the internalization of transferrin ( Figure S6B ), indicating that the RNAi was effective. We then measured NPC1L1-mediated cholesterol uptake following knockdown of CHC or m2. Loss of CHC or m2 significantly decreased the endocytosis of NPC1L1 as well as the internalization of cholesterol when cholesterol was replenished ( Figure 5B ). Quantifications showed that $50% of NPC1L1 endocytosis and cholesterol uptake were eliminated ( Figure 5C ). CHC knockdown also decreased the endocytosis of NPC1L1-EGFP in a surface biotinylation assay ( Figure S6C) . Finally, the endocytosis of NPC1L1-EGFP and the internalization of cholesterol were increased in a cholesterol concentration-dependent manner in control cells but were significantly attenuated in CHC or m2 RNAi cells (Figures S6D and S6E) . As a control, knockdown of caveolin-1 did not affect the internalization of NPC1L1 or cholesterol ( Figure S7 ), which is consistent with a previous report that cholesterol absorption is normal in caveolin-1-deficient mice (Valasek et al., 2005) .
Together, these data demonstrate that the NPC1L1 protein is internalized through clathrin/AP2-mediated endocytosis. When the transport of NPC1L1 from the PM is directly inhibited by loss of clathrin/AP2, the internalization of cholesterol is also decreased, indicating again that the endocytosis of NPC1L1 is required for cholesterol uptake.
Ezetimibe Blocks NPC1L1 Endocytosis and Cholesterol Uptake
Ezetimibe is a potent inhibitor of cholesterol absorption and has been approved as a novel hypocholesterolemic drug (Davis and Veltri, 2007) . NPC1L1 has been shown to bind ezetimibe and is the target of ezetimibe (Field et al., 2007; Hawes et al., 2007; Pfefferkorn et al., 2008; Weinglass et al., 2008; Garcia-Calvo et al., 2005) . However, how ezetimibe inhibits NPC1L1's function and blocks cholesterol absorption has not been fully understood. Since our data demonstrated that the endocytosis of NPC1L1 is required for cholesterol uptake, we then tested whether Cell Metabolism NPC1L1 Mediates Cholesterol Uptake via Endocytosis ezetimibe inhibits cholesterol uptake by blocking the endocytosis of NPC1L1. Cholesterol-depleted cells were treated with various concentrations of ezetimibe followed by cholesterol replenishment. Notably, ezetimibe inhibited the endocytosis of NPC1L1-EGFP in a concentration-dependent manner ( Figures  6B and 6C ). The internalization of cholesterol was blocked as well ( Figures 6B and 6C) . As a control, U18666A, a compound that interferes with LDL-derived cholesterol transport from endosomes/lysosomes to the ER likely by inhibiting NPC1 (Neufeld et al., 1999) , had no effect on NPC1L1-mediated cholesterol absorption. The results of a cell surface biotinylation assay confirmed that ezetimibe inhibited the endocytosis of NPC1L1-EGFP but not that of the transferrin receptor ( Figure 6D , compare lanes 4 and 5), suggesting that the effect of ezetimibe on NPC1L1 transport is specific.
We showed earlier that the CHC protein can be coimmunoprecipitated together with NPC1L1-EGFP protein when cholesterol is replenished ( Figure S5C ). We next performed a time-course study using the coimmunoprecipitation assay and found that cholesterol promoted the NPC1L1-clathrin complex formation ( Figure 6E ). The peak of the NPC1L1-clathrin interaction was observed after 20 min of cholesterol replenishment, and the interaction then decreased ( Figure 6E ). This phenomenon can be explained by the fact that CHC is only involved in the early stage of vesicular endocytosis and dissociates from cargo vesicles before the vesicles can fuse with the distal endocytic compartment. However, this cholesterol-induced NPC1L1-CHC complex was dramatically reduced in the presence of ezetimibe ( Figure 6E ). Similarly, ezetimibe inhibited the endocytosis of endogenous NPC1L1 as well as the internalization of cholesterol in human L02 hepatocytes ( Figures 6F and 6H) . Similar effects were observed in HuH7 cells (data not shown). On the other hand, ezetimibe did not show any significant effect on the exocytosis of NPC1L1, the efflux of cholesterol (Figure S8 ), or the uptake of fluorescently labeled LDL (DiI-LDL) ( Figure S9 ).
In summary, these data indicate that ezetimibe specifically blocks the incorporation of NPC1L1 into clathrin-coated vesicles, thereby inhibiting cholesterol absorption.
DISCUSSION
In this study, we observed cholesterol-regulated NPC1L1 shuttling: depletion of cholesterol causes the transport of NPC1L1 from ERC to PM, whereas replenishment of cholesterol results in the internalization of NPC1L1 (Figure 1) . Furthermore, the endocytosis of NPC1L1 requires microfilaments and the clathrin/AP2 complex ( Figure 4 ; Figure 5 ; Figure S6 ). More importantly, we propose that NPC1L1 mediates cellular cholesterol uptake through vesicular endocytosis, which is supported by five lines of evidence:
(1) NPC1L1 is required for free cholesterol uptake (Figure 2 ; Figure S2 ). (2) Replenishment of cholesterol, but not plant sterols, promotes the endocytosis of NPC1L1; meanwhile, cholesterol is internalized more efficiently than plant sterols (Figure 3 ). (3) Disruption of microfilaments blocks the endocytosis of NPC1L1 as well as the uptake of cholesterol (Figure 4) . (4) siRNA-mediated knockdown of the clathrin/AP2 complex attenuates the endocytosis of NPC1L1 and decreases cholesterol uptake ( Figure 5 ; Figure S6 ). (5) A cholesterol absorption inhibitor, ezetimibe, blocks NPC1L1 endocytosis and cholesterol internalization ( Figure 6 ).
Our data show that ezetimibe inhibits cholesterol internalization by blocking the endocytosis of NPC1L1 (Figure 6 ). Ezetimibe does so through preventing the association between NPC1L1 and clathrin/AP2, which is stimulated by cholesterol ( Figure 6E ). Interestingly, ezetimibe does not impede the internalization of the transferrin receptor or LDL receptor. These results are consistent with the previous finding that ezetimibe binds to NPC1L1 and is a highly selective inhibitor of cholesterol absorption (Garcia-Calvo et al., 2005; Davis et al., 2004) . How ezetimibe inhibits NPC1L1-clathrin complex formation is still unknown. To answer this question, we need to understand the endocytosis process of NPC1L1 and how cholesterol initiates this process. An interesting feature revealed by the sequence of the NPC1L1 protein is the presence of a sterol-sensing domain (SSD). The human genome encodes six SSD-containing proteins: HMGCR, SCAP, NPC1, Patched, TRC8, and NPC1L1 (Kuwabara and Labouesse, 2002) . It has been demonstrated that the SSDs of SCAP and NPC1 can directly bind cholesterol (Radhakrishnan et al., 2004; Ohgami et al., 2004) . Moreover, the binding of cholesterol causes a conformational change in SCAP that leads to the association of SCAP with an endoplasmic reticulum protein called Insig (Brown et al., 2002; Goldstein et al., 2006) . Conceivably, it is likely that cholesterol directly binds the SSD of NPC1L1, causes the conformational change of NPC1L1, and promotes the interaction between NPC1L1 and the clathrin/ AP2 complex. If this is the case, ezetimibe may compete with cholesterol for binding NPC1L1. Another possibility is that the interaction between ezetimibe and NPC1L1 may inhibit the cholesterol-induced conformational change of the NPC1L1 protein. It is also possible that ezetimibe interferes with the local distribution of cholesterol in the plasma membrane, which impedes cholesterol binding to NPC1L1. Further experiments will be required to test these possibilities.
Humans obtain cholesterol from de novo synthesis as well as through dietary and biliary cholesterol absorption. Compared with the abundantly available inhibitors of cholesterol (E) CRL-1601/NPC1L1-EGFP cells were treated as shown in (A). After replenishment with cholesterol for 0, 20, 40, and 60 min, cells were collected and subjected to coimmunoprecipitation with anti-EGFP antibodies. The immunoprecipitated proteins were separated by SDS-PAGE and analyzed by western blot with the indicated antibodies. (G) L02 cells were first treated with cholesterol-depleting medium in the absence or presence of 30 mM ezetimibe for 60 min. After being switched to cholesterol-replenishing medium for an additional 60 min, cells were washed, fixed, stained with filipin, and examined by two-photon confocal microscopy. Scale bar = 10 mm. biosynthesis, such as molecules of the statin family, ezetimibe is the only cholesterol absorption inhibitor known to target the NPC1L1 pathway thus far. One potential problem is that the responsiveness of different individuals to ezetimibe varies substantially. Ezetimibe can dramatically decrease plasma cholesterol concentrations in some individuals, while it is barely effective in others (Pisciotta et al., 2007) . Therefore, there is an urgent need for more cholesterol uptake inhibitory drugs. Our work provides the molecular basis for developing additional cholesterol absorption inhibitors. Moreover, the cell-based assay that we have established can potentially be used to screen for novel inhibitors of NPC1L1 endocytosis, which will block cholesterol uptake eventually.
Almost every kind of mammalian cell is capable of synthesizing cholesterol; however, de novo cholesterol synthesis is an energyconsuming process. It costs about 18 ATP, 27 NADPH, and 11 O 2 to generate a molecule of cholesterol from acetyl-CoA. Therefore, mammals obtain significant amounts of cholesterol from diet. Both animal sterol (cholesterol) and plant sterols are present in the intestinal lumen. Despite the structural similarity, cholesterol and plant sterols differ in the nature of their side chains ( Figure 3A) , and the functions of cholesterol cannot be completely replaced by plant sterols (Xu et al., 2005) . In fact, humans and animals selectively absorb cholesterol from diet. This important phenomenon is partly explained by the substrate specificity of ABCG5/ G8. Previous studies have shown that ABCG5/G8 may preferentially secrete plant sterols out of cells (Yu et al., 2004) , thereby ensuring the selective uptake of cholesterol. However, a massive amount of cholesterol is also pumped out by ABCG5/G8 (Yu et al., 2002b) . Meanwhile, the rank order of the efficiency of absorption of different sterols is maintained in sitosterolemic patients and ABCG5/G8-deficient mice (Yu et al., 2002a; Lutjohann et al., 1995; Iyer et al., 2005) , indicating that substrate specificity of ABCG5/G8 is not the sole mechanism for selective cholesterol absorption. We have observed that NPC1L1 efficiently mediates the internalization of cholesterol, but not other sterols (Figure 3) . Brown et al. (2007) have also reported consistent results. These data indicate that besides ABCG5/G8-mediated selective excretion of plant sterols, NPC1L1 represents another layer of cholesterol absorption regulation: selective cholesterol internalization. Although it has been reported that NPC1L1 is responsible for the absorption of both cholesterol and sitosterol (Yamanashi et al., 2007; Davis et al., 2004) , our data suggest that cholesterol is the most efficient substrate for NPC1L1. NPC1L1 protein recycles between the plasma membrane (PM) and endocytic recycling compartment (ERC). When the extracellular cholesterol concentration is high, cholesterol is incorporated into the PM and is sensed by cell surface-localized NPC1L1. NPC1L1 and cholesterol are then internalized together through clathrin/AP2-mediated endocytosis and transported along microfilaments to the ERC in vesicles. The ERC is where massive amounts of cholesterol and NPC1L1 are stored. When the intracellular cholesterol level is low, ERC-localized NPC1L1 moves back to the PM along microfilaments in order to absorb cholesterol. Notably, ezetimibe prevents NPC1L1 from entering the AP2-mediated clathrin-coated vesicles, thus inhibiting the endocytosis of NPC1L1 and eventually decreasing cholesterol absorption.
According to our results, we propose a model illustrating the pathway of dietary or biliary cholesterol absorption, depicted in Figure 7 . After being incorporated into the PM of enterocytes or hepatocytes, free cholesterol is then sensed by PM-localized NPC1L1, and they are internalized together through clathrin/ AP2-mediated endocytosis. These NPC1L1-positive and cholesterol-rich vesicles move along microfilaments to the ERC, where massive amounts of cholesterol and NPC1L1 are stored. When intracellular cholesterol levels are low, NPC1L1 moves back to the PM along the microfilaments in order to absorb cholesterol. Notably, ezetimibe prevents NPC1L1 from entering the AP2-mediated clathrin-coated vesicles, thus inhibiting the endocytosis of NPC1L1 and eventually decreasing cholesterol absorption.
EXPERIMENTAL PROCEDURES
A complete description of primary antibodies and other methods are available in the Supplemental Experimental Procedures.
Materials and Plasmids
We obtained horseradish peroxidase-conjugated donkey anti-mouse and anti-rabbit IgG from Jackson ImmunoResearch Laboratories; filipin, nocodazole, and cytochalasin D from Sigma; Alexa Fluor 555 donkey anti-rabbit IgG and iron-loaded transferrin-rhodamine conjugate from Invitrogen; sulfosuccinimidyl 6-(biotinamido) hexanoate and NeutrAvidin agarose from Pierce; methyl-b-cyclodextrin (CDX) from Cyclodextrin Technologies Development, Inc.; all sterols from Steraloids, Inc.; and other reagents from previously described sources (Cao et al., 2007) . The purity of cholesterol was above 99% as measured by gas chromatography/mass spectrometry (GC/MS) in the F.-J. Nan laboratory (Shanghai Institute of Materia Medica, Shanghai, China). Lipoprotein-deficient serum (LPDS, density > 1.215 g/ml) was prepared from newborn calf serum by ultracentrifugation (Goldstein et al., 1983) .
The coding region of human NPC1L1 was amplified from human liver cDNA by standard PCR and cloned into pEGFP-N1 vector. The resulting plasmid encodes full-length human NPC1L1 fused with EGFP at the COOH terminus. The coding region of Rab11a was amplified from HEK293 cell cDNA and cloned into pDsRed-monomer-C1 vector. The resulting construct encodes DsRed-Rab11a.
Cell Culture CRL-1601 (a McArdle RH7777 rat hepatoma cell line), L02 (a human liver cell line), and HuH7 (a human hepatoma cell line) cells were grown in monolayer at 37 C in 5% CO 2 . The cells were maintained in medium A (Dulbecco's modified Eagle's medium containing 100 units/ml penicillin and 100 mg/ml streptomycin sulfate) supplemented with 10% FBS. Cholesterol-depleting medium was medium A supplemented with 5% LPDS, 10 mM compactin, 50 mM mevalonate, and 1.5% CDX. Cholesterol-replenishing medium contained medium A supplemented with 5% LPDS, 10 mM compactin, 50 mM mevalonate, and different concentrations of cholesterol/CDX. The sterol/ CDX inclusion complexes were prepared as described previously (Brown et al., 2002) .
Cell Surface Biotinylation Assay
After being washed twice with ice-cold PBS and treated with 1mg/ml sulfosuccinimidyl 6-(biotinamido) hexanoate in PBS for 40 min at 4 C, cells were washed with ice-cold buffer A (20 mM Tris-HCl [pH 8.0] and 150 mM NaCl) and incubated in buffer A for 15 min at room temperature. Cells were then collected by scraping and lysed in buffer B (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 1% NP-40). Each sample of cell lysates was incubated with 100 ml 50% (v/v) NeutrAvidin agarose and rotated overnight at 4 C. The agarose beads were then washed three times with buffer B. Biotinylated proteins binding to the beads were eluted by incubation with SDS-PAGE sample buffer at 37 C for 30 min and analyzed by SDS-PAGE followed by western blot.
RNA Interference
Duplexes of siRNA were synthesized by Genepharma (Shanghai, China). The siRNA targeting rat clathrin heavy chain (CHC) was described previously (Radulescu et al., 2007) . The sequences of siRNAs targeting rat AP2 m2 and caveolin-1 were 5 0 -AAGGCATGAAGGAATCACAGA-3 0 and 5 0 -AAGCAAGTG TACGACGCGCAC-3 0 , respectively. The siRNA against vesicular stomatitis virus G protein (VSV-G), used as a control, was described previously (Song et al., 2005) . Transfection of siRNAs was carried out as described previously (Sever et al., 2003) .
Immunofluorescence Microscopy Cells were fixed with 4% paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100 in PBS. Cells were then blocked with 1% BSA in PBS and labeled with primary antibodies and fluorescent secondary antibodies as described in the figure legends. Confocal immunofluorescence microscopy was performed using a Leica TCS SP2 laser scanning microscope. In each experiment, images of the same channel were acquired at identical laser output, gain, and offset.
Filipin Staining
A fresh 5 mg/ml stock solution of filipin was prepared in ethanol. After fixation as described earlier, cells were washed twice with PBS and stained with 50 mg/ ml filipin in the dark for 30 min at room temperature followed by three washes with PBS. Filipin signals of stained cells were analyzed with a Zeiss LSM 510 confocal microscope equipped with a two-photon laser using an excitatory wavelength of 720 nm. Red pseudocolor was assigned to show the filipin signal. In each experiment, images were acquired at identical laser output, gain, and offset.
Fluorescence Quantification
For quantification of intracellular NPC1L1 or cholesterol abundance, two circles, one outlining the whole cell and the other beneath the plasma membrane, were drawn manually. After subtraction of the background, the fluorescence intensities in each circle were measured by Image-Pro Plus 5.02 and regarded as whole-cell and intracellular fluorescence intensity, respectively. The intensity of each cell was arbitrarily defined as 1, against which the intracellular intensity was normalized. For each time point, 50 cells were randomly selected and calculated. The data shown in the figures are representative of four or more independent experiments. For quantification of total cellular cholesterol, a similar method was employed except that the intracellular circles were omitted. The total cholesterol of control cells at time point À60 min was defined as 1, against which the total cellular cholesterol at other time points was normalized.
For quantification of cells with NPC1L1-EGFP PM localization, $100 cells in each treatment were randomly selected and counted. The results are presented as the percentage of cells with NPC1L1-EGFP PM localization. Three independent experiments were performed, and one representative is presented in the figures.
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